The Risk of Multiple Myeloma Is Reduced in Metformin Initiators: A Retrospective Cohort Study in Taiwanese Patients with Type 2 Diabetes Mellitus.

ABSTRACT:

Background

Whether metformin might reduce the risk of multiple myeloma (MM) has not been extensively researched in humans.

Methods

The study subjects were enrolled from the reimbursement database of Taiwan's National Health Insurance. A total of 739,553 patients who had a new diagnosis of type 2 diabetes mellitus during 1999-2009 were identified. They were categorized as metformin initiators (metformin (+)) and non-metformin initiators (metformin (-)) based on the prescriptions of antidiabetic drugs that included metformin and did not include metformin within the initial 12 months, respectively. MM incidence was calculated after the initial 12 months of treatment group assignment until 31 December 2011. Hazard ratios based on intention-to-treat (ITT) and per-protocol (PP) ap

SUBMITTER: Tseng CH 

PROVIDER: S-EPMC9688273 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature